Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mucoid exopolysaccharide P. aeruginosa immune globulin
- Development stage
- Phase 2
- Lead developer
- National Center for Research Resources
- Administration
- Intravenous
01
Overview
Mucoid exopolysaccharide P. aeruginosa immune globulin (MEP IGIV) is an investigational intravenous immunoglobulin (IGIV) biologic developed for the treatment of cystic fibrosis (CF). It specifically targets patients colonized with mucoid strains of *Pseudomonas aeruginosa*. The drug consists of a human immunoglobulin preparation enriched with high titers of opsonic antibodies directed against the mucoid exopolysaccharide (MEP), or alginate, which forms the protective biofilm/capsule of the bacteria. The mechanism of action involves the binding of these antibodies to the MEP capsule, which promotes complement deposition and subsequent opsonophagocytic killing by host immune cells—a defense mechanism that CF patients typically fail to develop naturally against mucoid strains. It has been evaluated in Phase II clinical trials sponsored by the National Center for Research Resources (NCRR).
- Other names
- mucoid exopolysaccharide Pseudomonas aeruginosa immune globulinalginate immune globulin
02
Targets
C1Q (Complement C1q)AlginateFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on mucoid exopolysaccharide P. aeruginosa immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mucoid exopolysaccharide P. aeruginosa immune globulin.